Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Update

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 5,110,000 shares, a decrease of 28.5% from the February 28th total of 7,150,000 shares. Based on an average daily trading volume, of 2,430,000 shares, the short-interest ratio is currently 2.1 days. Currently, 14.2% of the company's stock are short sold.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CKPT. HC Wainwright reaffirmed a "neutral" rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th. Lake Street Capital reissued a "hold" rating and issued a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $4.80 price objective on shares of Checkpoint Therapeutics in a report on Monday.

Checkpoint Therapeutics Price Performance

NASDAQ CKPT traded down $0.01 during trading hours on Tuesday, hitting $4.04. 42,917 shares of the company's stock traded hands, compared to its average volume of 1,120,541. The firm's 50-day moving average is $3.33 and its 200-day moving average is $3.28. The company has a market capitalization of $197.04 million, a PE ratio of -2.19 and a beta of 1.41. Checkpoint Therapeutics has a 52-week low of $1.38 and a 52-week high of $4.50.

Remove Ads

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.47). Equities research analysts predict that Checkpoint Therapeutics will post -0.94 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $3.15, for a total value of $32,542.65. Following the completion of the sale, the chief executive officer now directly owns 3,775,019 shares in the company, valued at approximately $11,891,309.85. This trade represents a 0.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO William Garrett Gray sold 74,110 shares of the business's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the sale, the chief financial officer now owns 1,458,644 shares in the company, valued at $5,353,223.48. The trade was a 4.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 93,674 shares of company stock worth $336,011 over the last 90 days. Company insiders own 2.10% of the company's stock.

Institutional Trading of Checkpoint Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in Checkpoint Therapeutics during the 3rd quarter valued at about $30,000. SBI Securities Co. Ltd. acquired a new position in shares of Checkpoint Therapeutics during the fourth quarter worth about $32,000. PUREfi Wealth LLC purchased a new stake in shares of Checkpoint Therapeutics during the fourth quarter worth approximately $32,000. Stifel Financial Corp acquired a new stake in Checkpoint Therapeutics in the fourth quarter valued at approximately $32,000. Finally, Ameriflex Group Inc. acquired a new position in Checkpoint Therapeutics during the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 22.00% of the company's stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.